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Abstract
Objective To estimate the potential cost effectiveness of a
population-wide risk factor reduction programme aimed at preventing
cardiovascular disease.
Design Economic modelling analysis.
Setting England and Wales.
Population Entire population.
Model Spreadsheet model to quantify the reduction in cardiovascular
disease over a decade, assuming the benefits apply consistently for
men and women across age and risk groups.
Main outcome measures Cardiovascular events avoided, quality
adjusted life years gained, and savings in healthcare costs for a given
effectiveness; estimates of how much it would be worth spending to
achieve a specific outcome.
Results A programme across the entire population of England and
Wales (about 50 million people) that reduced cardiovascular events by
just 1% would result in savings to the health service worth at least £30m
(€34m; $48m) a year compared with no additional intervention. Reducing
mean cholesterol concentrations or blood pressure levels in the
population by 5% (as already achieved by similar interventions in some
other countries) would result in annual savings worth at least £80m to
£100m. Legislation or other measures to reduce dietary salt intake by
3 g/day (current mean intake approximately 8.5 g/day) would prevent
approximately 30 000 cardiovascular events, with savings worth at least
£40m a year. Legislation to reduce intake of industrial trans fatty acid
by approximately 0.5% of total energy content might gain around 570
000 life years and generate NHS savings worth at least £230m a year.
Conclusions Any intervention that achieved even a modest
population-wide reduction in any major cardiovascular risk factor would
produce a net cost saving to the NHS, as well as improving health. Given
the conservative assumptions used in this model, the true benefits would
probably be greater.
Introduction
Cardiovasculardiseases(principallycoronaryheartdiseaseand
stroke) together account for more than 150 000 deaths a year
in the United Kingdom.
1 Cardiovascular diseases affect more
thanfivemillionpeople,andannualcostsexceed£30bn(€34bn;
$48bn).
2 However, more than 80% of premature (at age <75)
cardiovascular disease is avoidable.
3 4
The UK government strategy for the primary prevention of
cardiovascular disease therefore focuses on a dual approach.
NationalHealthService(NHS)healthcheckstodetectandtreat
people at high risk are underpinned by policies benefiting the
entire population, such as smoke-free legislation and the
progressive reduction in the salt content of processed food.
5 6
In 2004 the Wanless report suggested that a more “fully
engaged”population-widepreventionstrategymightsave£36bn
a year.
7 Abelson estimated comparable savings in Australia.
8
More recently, the Trust for America’s Health calculated a six
for one return on investment for population-wide approaches
to prevention in the United States.
9
Elsewhere, many studies have suggested that tobacco control
programmes are cost saving.
10 Likewise, dietary salt reduction
policies consistently seem to be very cost effective,
11 or even
cost saving.
12 13 However, data on the economics of other
population based dietary interventions, such as the eradication
of trans fats or reduction of saturated fat, are much scarcer.
10-15
The effectiveness and cost effectiveness of population based
dietary approaches to prevention of cardiovascular disease in
theUKarelessclear.TheDepartmentofHealththereforeasked
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RESEARCHthe National Institute for Health and Clinical Excellence to
develop guidance on a public health programme aimed at
preventing cardiovascular disease in whole populations. To
inform this programme, we built a generic economic model to
estimate the comparative cost effectiveness of such
interventions.Afterinitialdevelopmentandtesting,weapplied
this model to two general scenarios involving small decreases
in population levels of blood pressure or total cholesterol
concentrations and to two specific legislative interventions
aimed at reducing the dietary intake of salt and trans fats.
Methods
After consultation with stakeholders, we built a generic
spreadsheetmodelquantifyingarangeofpossibleinterventions,
whichcouldestimatecasesofcardiovasculardiseaseanddeaths
duetocardiovasculardiseasepreventedorpostponed,lifeyears
andqualityadjustedlifeyears(QALYs)gained,andcostsavings
to the NHS resulting from cases prevented or postponed. After
initial development and testing, we applied this model to two
general scenarios involving small decreases in blood pressure
andtotalcholesterolconcentrationandtotwospecificexamples
of legislative interventions to reduce the dietary intakes of salt
and trans fats.
Model development
We developed a spreadsheet model in four successive stages:
costs,casesprevented,individualbenefits,thenaggregatingthe
benefits.
Determining NHS costs and QALYs lost for one
case of cardiovascular disease
For costing, we adapted the principles of the Sheffield
prevention model, updating unit costs and otherwise inflating
to2008.
16Thesearedetailedinthewebappendix.Allnewcosts
and inflation indices came from Curtis.
17
Weestimatedtheexpectedlifetimecosts,lifeyears,andQALYs
after a first cardiovascular event as a function of age and sex.
Comparing these with life expectancy without an event then
gave the loss in life years and QALYs from such an event. For
example, we considered the case of a 65 year old man who
developed stable angina. We combined life expectancy data
from the government actuary’s department with quality of life
data from Sheffield to estimate a discounted quality adjusted
life expectancy of 8.50 QALYs.
16 We used data from Ward et
al to estimate lifetime treatment costs with stable angina of
£2338 and a loss of 2.12 QALYs.
16 We then did similar
calculations for a 65 year old man having a first cardiovascular
event to estimate lifetime treatment costs and QALYs lost. The
range of cardiovascular events reflected the typical age
dependent case mix.
16 We then repeated this process for men
and women at all ages from 40 to 90 years (see appendix).
Assessing pattern of cases of cardiovascular
disease prevented or postponed for intervention
of known effectiveness, using Framingham risk
equation applied to single birth cohort
We assessed the pattern of cases prevented or postponed by an
intervention of known effectiveness. We used the Framingham
risk equations to generate the expected pattern of first
cardiovascular events according to the person’s age, sex, and
risk of cardiovascular disease.
18
Toestimatetheeffectofanintervention,weusedarelativerisk
applied to the annual risk of a first cardiovascular event. This
generated expected reductions in first cardiovascular events
over a 10 year period. The appendix shows an example for a 65
year old man with a 10 year risk of cardiovascular disease of
12.5% and an intervention achieving an annual relative risk of
0.9. We then did similar calculations for all men and women in
10yearagebandsfrom45to75.Thedistributionofriskfactors
in 10 year age groups was based on the Joint British Societies’
guidelines.
19 For ease of modelling, we took the “under 10%”
cardiovascular disease risk group at 7.5% and the “over 30%”
risk group at 32.5%.
Combining results from first two stages to
estimate potential outcomes for single
combination of age, sex, and risk
We then combined the results of the first two stages to produce
estimatesofdeathsprevented,lifeyearsgained,QALYsgained,
andcostsavingsseparatelyforeachgroup.Theappendixshows
an illustrative example for an intervention with relative risk 0.9
applied to 65 year old men.
Generating output for men and women of all
ages, then aggregating results to give total
estimated NHS costs and QALYs gained at level
of entire England and Wales population of 50
million
To reflect the nature of the risk equation and the assumptions
needed, we conservatively estimated benefits from a reduction
in the number of cases over a 10 year time horizon. We then
expressed the output on an annual basis. We then aggregated
the results across these distributions to give us expected
outcomes for men and women of unknown cardiovascular
disease risk in 10 year age bands.
Wecalculatedthetotalpopulationeffectsfor10yearagegroups
inEnglandandWalesbyusingdatafromtheOfficeforNational
Statistics.
20 We then calculated the total population without
cardiovascular disease eligible for primary prevention by
subtracting the Sheffield estimate of the people with a history
of cardiovascular disease from the population total.
16 Scaling
up the group results then provided the estimates for the total
population (see appendix).
WeusedNICE’sstandardannualdiscountrateof3.5%forboth
costsandoutcomes.Wehaveconvertedtotalsavingsintoannual
equivalent savings across each of the 10 years, after allowing
for the discounting applied. Full technical details of the model
are available in the appendix and on the NICE website.
21
Results
Generic population-wide interventions
Reducing the cardiovascular risk of the population by just 1%
sustained over 10 years would prevent approximately 25 000
new cases of cardiovascular disease and 3500 deaths from
cardiovasculardisease.Thiswouldgainaround98000QALYs
andwouldgeneratetotal(discounted)savingsofapproximately
£265m, equivalent to annual savings across the 10 years of the
programme of approximately £30m, compared with no
additional intervention (table 1). Here, and elsewhere, a large
part of the substantial gain in QALYs is due to the prevention
of non-fatal events that strongly affect quality of life. The
number of QALYs gained therefore exceeds the number of life
years gained.
Reducing population blood pressure levels or total cholesterol
concentrations by 5% would result in correspondingly larger
healthgains.Annualequivalentsavingswouldbeapproximately
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RESEARCH£100 million for blood pressure (table 2) and £80 million for
cholesterol (table 3).
Specific interventions
Legislation to reduce salt intake
DietarysaltintakeinEnglandandWalesaveragesapproximately
8.5 g/day. A reduction of 3 g/day in salt intake represents a
conservative estimate of the potential effects of specific
legislation, based on the 6 g reduction achieved in Finland,
Japan, and elsewhere.
22 Reducing salt intake by 3 g/day might
reduce mean population systolic blood pressure by
approximately2.5mmHg.
23Thiswouldequatetoa2%decrease
intheriskreductionmodel.
23Thiswouldpreventapproximately
4450 deaths from cardiovascular disease, with total discounted
savings overall of approximately £347m over a decade,
representing equivalent annual savings of approximately £40m
(table 4). Any salt reduction intervention totalling up to £40m
a year would therefore still be cost saving.
Legislation to ban industrial fats
Industrial trans fats account for approximately 0.8% of total
UK dietary energy intake.
23 Based on experience in Denmark,
transfatlevelscouldbereducedbyapproximately0.5%oftotal
UK dietary energy intake.
15 24 This would reduce the relative
risk of death from cardiovascular disease by approximately
6%.
25 Applying these benefits to the entire England and Wales
population would prevent approximately 2700 deaths annually
and thus gain 570 000 life years, saving the equivalent of
approximately £235m a year (table 5). An intervention costing
up to £230m a year would therefore still be cost saving if it
achieved the desired reduction in trans fats.
Sensitivity analyses
We did an extensive series of sensitivity analyses. In brief,
savings occurred even when the background risk was reduced
by 5% or 50%. Corresponding increases of 5% and 50% are
also shown for completeness in the web appendix.
Discussion
Our results strongly suggest that any policy intervention
achieving even a 1% population-wide reduction in risk of
cardiovascular disease can be expected to produce a net cost
saving to the NHS, as well as decreasing losses in productivity
and improving health. Only if a very large sum of money needs
to be spent on implementing the legislation would this cease to
be the case. Our findings are reassuringly consistent with
analyses from the United States, Australia, and the UK
Treasury.
7-15 26 Likewise, a five year campaign on salt reduction
by the UK Food Standards Agency cost approximately £15m
and achieved a reduction of 0.9 g/day in average salt intake.
This was estimated to prevent approximately 6000
cardiovascular deaths a year, with estimated savings totalling
some£1.5bn,or£300mayear.
6Furthermore,analysesofcohorts
withlowercardiovascularriskshowfewercardiovascularevents
delayed to an older age and incurring substantially lower
Medicare costs.
27
The 5% reductions modelled for systolic blood pressure and
cholesterol concentration are entirely consistent with the actual
falls achieved in regional programmes such as North Karelia,
Stanford, and HeartBeat Wales.
28 29 Furthermore, much larger
reductions in entire populations have been documented since
the 1980s. For instance, cholesterol reductions of 22% in
Finland, 14% in Iceland, 10% in Sweden, and 6% in the United
States have been reported.
30 31 32 33 Likewise, blood pressure
reductions of 8% in England and 6% in Finland have been
reported.
29 30
Our 0.5% reduction in industrial trans fats represents a
conservative estimate of what is possible, given past UK trends
and recent Danish experience of successful eradication.
34
Industrial trans fats have now been banned in five European
countries:Denmark,Switzerland,Austria,Sweden,andIceland.
Manufacturers have adapted rapidly, easily, and with minimal
costs.
35 We would suggest that the UK is unlikely to be very
different. Furthermore, important inequalities exist, given the
very high consumption of trans fats recently reported in some
disadvantagedgroups(exceeding6%ofdailyenergy).
35Benefits
in deprived communities might therefore be even larger.
Strengths of analysis
Our spreadsheet model allows a relative risk to be applied to
each year’s risk of primary cardiovascular disease in the
population. It also allows percentage reductions in cholesterol
concentration and systolic blood pressure to be considered
separately for men and women. The model is designed to be
transparent and involves relatively few assumptions, each of
whichcanbeeasilytested.Furthermore,theestimatesarebased
on a series of conservative assumptions, so the true benefits are
likely to be substantially larger.
WequantifiedonlyNHSsavings.Netsocialsavingswillclearly
be much larger. The model focuses on primary prevention of
cardiovasculardisease.Allpopulation-wideriskfactorreduction
programmes considered in this report would also benefit the
five million patients with recognised cardiovascular disease in
the UK.
36 37 Substantial reductions in diabetes, many common
cancers, and other chronic diseases would also occur.
37
This simple model assumed a uniform distribution of burden
and benefit across social groups. In fact, deprived groups have
disproportionatelymorediseaseandwouldthusgainmorefrom
population-wide risk factor reductions. Absolute inequalities
would also be decreased.
38
This is not simply a cost of illness study. It is a modelling study
thatshowstherangeofpossiblecostsavingsandQALYbenefits
from a range of plausible interventions. It therefore allows an
upper limit to be placed on the cost at which any such
intervention would be worthwhile. Greater complexity in the
modelmightleadtoadditionalprecisionintheresults.However,
wesuggestthatthisadditionalprecisionmightmakesurprisingly
little difference to the key policy decisions.
The sensitivity analyses were reassuring and suggested that
using a different risk “engine” to drive the model would have
a relatively modest effect. The model is based on the original
Framingham equations and the same risk score as the Joint
British Societies’ guidelines, which is widely used and
understood. It also reflects the model that was presented to the
NICE Programme Development Group to assist in their
deliberations and inform their subsequent key
recommendations.
35
Limitations of analysis
Our conclusions are clearly subject to several important
limitations reflecting the nature of the model. Apart from the
increased mortality immediately after a first non-fatal primary
cardiovascularevent,wemadenoattempttoconsiderrecurrent
events or subsequent deaths. The estimates of deaths avoided,
life years gained, and cost savings are thus likely to be
underestimates,makingtheanalysissomewhatconservative.A
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cases; gains over a lifetime would clearly be greater.
The analysis was pragmatically limited to people aged between
40 and 79 years at the time of the intervention. However, given
theveryhighratesofcardiovasculareventsinpeopleagedover
80, substantial additional benefits might be expected. Our
interventionsassumedrelativelyuniformeffectsacrossageand
risk groups by definition. However, the subsequent changes in
specific risk factors included age gradients and considered men
and women separately.
In this study, the counterfactual (no intervention) implicitly
assumesthatthepopulationriskofcardiovasculardiseasewould
remain constant. However, there may be a “natural” increase
or decrease in cardiovascular risk without population-wide
interventions. Modest changes could also follow targeted
interventionsinsubgroups.Eitherofthesescenariosmightaffect
future costs and QALYs.
Finally,thisinitialmodellinglacksafullprobabilisticsensitivity
analysis, because many essential data inputs (such as the
distribution of risk factors in the population) were readily
availableonlyaspointestimates.However,therangeofchanges
in risk factors and their effects quantified in the results tables
and web appendices provide a satisfactory and rigorous
sensitivity analysis. Future studies might usefully include a full
probabilisticsensitivityanalysistoformallytesttheuncertainties
inherent in the various modelling assumptions.
Implications of findings
We estimated that a 1% reduction in the relative risk of
cardiovasculardiseasewouldgeneratediscountedNHSsavings
ofapproximately£30mayearinEnglandandWales,compared
with no additional intervention, This estimate is considerably
less than 1% of the £7bn healthcare costs calculated by
Luengo-Fernández et al.
2 However, this again highlights the
conservative approach taken in our modelling.
In terms of opportunity cost, any programme that reduces the
rateofdeathfromcardiovasculardiseaseby1%iscosteffective
uptocostsof£30m,aslongasnoalternativeprogrammecauses
a bigger reduction at the same costs or the same reduction at
lower costs. Varying the underlying Framingham risk equation
to include newer values such as QRISK2 will also be useful.
39
However, the resulting changes are likely to be small.
Furthermore, subsequent research should ensure that such
models remain up to date, accessible, and credible. A better
quantification of our understanding of causal pathways for
cardiovascular disease will be challenging but important.
Animportantfactoristhefeasibilityofpopulation-widedietary
changes—for instance, in salt consumption. Cultural aspects
are important in some countries, such as salted fish in Portugal
and salted vodka further east. However, most populations now
live in a global economy. We eat what is available, affordable,
and acceptable. In our UK study population, that means that
more than 80% of consumed salt is concealed in processed
food.
22 35IntheUK,mediacampaignsandvoluntaryagreements
with the food industry have already achieved a 1 g reduction in
salt consumption. We therefore suggest that a 3 g reduction
might be entirely feasible by using more muscular regulatory
approaches. The 6 g reductions in Finland and Japan were
achieved in spite of cultural traditions and resistance from the
industry.
22 29Furthermore,reductionsof5-10%inthesaltcontent
of any specific food during one year are simply not noticed by
most consumers. This is because human taste buds adapt very
quickly.SalthasalreadybeensubstantiallydecreasedintheUK
and several other countries, with no evidence of widespread
compensation by consumers.
35
This paper does not detail the specific costs of particular
programmes. It is making a more general argument. Given the
benefits in terms of increased health and reduced healthcare
costs, the sorts of programmes we have seen work in other
countries must surely also be cost effective here.
Conclusions
Our model is relatively simple and transparent with clear
limitations.However,thecumulativeconservativeassumptions
mean that the benefits and cost savings are almost certainly
underestimated. The findings are reassuringly consistent with
results from very different methods in the United States,
Australia, and the UK Treasury.
7-9 26 27 40 Population-wide
prevention interventions seem to be both powerful and cost
saving.
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RESEARCHTables
Table 1| Discounted outcomes for intervention achieving given relative risk reduction sustained over 10 years
Annual equivalent
savings (£m) Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000)
Relative risk
reduction
3 26 10 7 0.3 2 0.001
15 132 49 37 1.7 12 0.005
31 265 98 74 3.5 25 0.01
62 530 197 149 7.0 50 0.02
93 796 295 224 10 75 0.03
123 1063 394 299 14 100 0.04
154 1330 493 374 18 125 0.05
186 1597 592 449 21 150 0.06
217 1865 692 524 25 175 0.07
248 2133 791 600 28 201 0.08
279 2402 891 675 32 226 0.09
310 2671 990 751 35 251 0.1
467 4024 1492 1132 53 378 0.15
626 5389 1997 1516 71 507 0.2
786 6766 2507 1903 89 637 0.25
947 8155 3021 2294 108 768 0.3
1110 9557 3540 2689 126 900 0.35
1275 10 971 4062 3088 145 1033 0.4
1440 12 397 4589 3490 164 1168 0.45
1607 13 836 5121 3895 183 1304 0.5
QALY=quality adjusted life year.
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RESEARCHTable 2| Discounted outcomes for intervention with given percentage reduction in systolic blood pressure sustained over 10 years
Annual equivalent
savings (£m) Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000)
Percentage reduction in
systolic blood pressure
10 86 33 24 1.1 8 0.5
20 173 65 48 2.2 16 1
30 260 98 72 3.3 24 1.5
40 347 131 96 4.4 32 2
50 435 164 121 5.5 40 2.5
61 522 197 145 6.7 48 3
71 610 230 169 7.8 57 3.5
81 699 263 194 8.9 65 4
91 787 296 219 10.0 73 4.5
102 876 330 243 11.2 81 5
QALY=quality adjusted life year.
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RESEARCHTable 3| Discounted outcomes for intervention with given percentage reduction in cholesterol concentration sustained over 10 years
Annual equivalent
savings (£m) Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000)
Percentage reduction
in cholesterol
8 68 26 19 0.9 6 0.5
16 136 51 38 1.7 13 1
24 205 77 57 2.6 19 1.5
32 274 103 76 3.5 25 2
40 343 129 95 4.4 32 2.5
48 412 155 114 5.3 38 3
56 481 181 134 6.1 45 3.5
64 551 208 153 7.0 51 4
72 621 234 172 7.9 58 4.5
80 691 260 192 8.8 64 5
QALY=quality adjusted life year.
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RESEARCHTable 4| Discounted estimates of total population effects from reduction of 3 g/day in salt intake sustained over 10 years, by age and sex
Annual equivalent
savings (£m) Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000) Age groups (years)
Men:
5 47 21 12 0.51 4.4 40-49
6 53 21 16 0.71 4.9 50-59
6 49 17 15 0.74 4.8 60-69
3 28 8 7 0.45 3.1 70-79
Women:
6 48 19 11 0.39 4.0 40-49
5 46 18 13 0.51 3.8 50-59
5 45 16 14 0.64 3.9 60-69
4 31 10 9 0.48 3.2 70-79
40 347 131 96 4.43 32.2 Totals
Any apparent anomalies with addition are due to rounding effects.
QALY=quality adjusted life year.
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RESEARCHTable 5| Discounted estimates of total population effects from intervention based on legislation against trans fats sustained over 10 years,
by age and sex
Annual equivalent
savings (£m) Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000) Age groups (years)
Men:
28 243 107 64 2.7 23 40-49
37 322 129 96 4.3 30 50-59
39 335 119 100 5.1 33 60-69
23 200 57 51 3.3 23 70-79
Women:
27 234 92 53 1.9 19 40-49
28 239 94 68 2.7 20 50-59
30 261 95 82 3.7 23 60-69
23 199 61 58 3.1 21 70-79
235 2033 754 571 26.8 191 Totals
QALY=quality adjusted life year.
Any apparent anomalies with addition are due to rounding effects.
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RESEARCH